Htin Lin Aung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2617412/publications.pdf

Version: 2024-02-01

1040056 888059 31 341 9 17 citations h-index g-index papers 31 31 31 531 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The fourth national tuberculosis prevalence survey in Myanmar. PLOS Global Public Health, 2022, 2, e0000588.	1.6	5
2	<i>Mycobacterium smegmatis</i> Resists the Bactericidal Activity of Hypochlorous Acid Produced in Neutrophil Phagosomes. Journal of Immunology, 2021, 206, 1901-1912.	0.8	8
3	Measuring Catastrophic Costs Due to Tuberculosis in Myanmar. Tropical Medicine and Infectious Disease, 2021, 6, 130.	2.3	10
4	Genomic Profiling of <i>Mycobacterium tuberculosis</i> Strains, Myanmar. Emerging Infectious Diseases, 2021, 27, 2847-2855.	4.3	8
5	Translating whole-genome-sequence data for drug-resistant Mycobacterium tuberculosis diagnostics in clinics. New Zealand Medical Journal, 2021, 134, 115-117.	0.5	O
6	Geno-Spatial Distribution of Mycobacterium Tuberculosis and Drug Resistance Profiles in Myanmar–Thai Border Area. Tropical Medicine and Infectious Disease, 2020, 5, 153.	2.3	10
7	Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathogens, 2020, 16, e1008287.	4.7	51
8	Title is missing!. , 2020, 16, e1008287.		0
9	Title is missing!. , 2020, 16, e1008287.		O
10	Title is missing!. , 2020, 16, e1008287.		0
11	Title is missing!. , 2020, 16, e1008287.		0
11 12	Title is missing!. , 2020, 16, e1008287. Tackling tuberculosis in the indigenous people of New Zealand. Lancet Public Health, The, 2019, 4, e496.	10.0	5
		10.0	
12	Tackling tuberculosis in the indigenous people of New Zealand. Lancet Public Health, The, 2019, 4, e496. Reducing the burden of tuberculosis in the MÄori, the Indigenous people of New Zealand. The Lancet		5
12	Tackling tuberculosis in the indigenous people of New Zealand. Lancet Public Health, The, 2019, 4, e496. Reducing the burden of tuberculosis in the MÄori, the Indigenous people of New Zealand. The Lancet Global Health, 2019, 7, e845. Pyrazolo[1,5- <i>>a</i> > pyridine Inhibitor of the Respiratory Cytochrome <i>>bcc</i> > Complex for the	6.3	5
12 13 14	Tackling tuberculosis in the indigenous people of New Zealand. Lancet Public Health, The, 2019, 4, e496. Reducing the burden of tuberculosis in the MÄori, the Indigenous people of New Zealand. The Lancet Global Health, 2019, 7, e845. Pyrazolo[1,5- <i>a</i> pyridine Inhibitor of the Respiratory Cytochrome <i>bcc</i> Complex for the Treatment of Drug-Resistant Tuberculosis. ACS Infectious Diseases, 2019, 5, 239-249. Association between anti-tuberculosis drug resistance-conferring mutations and treatment	6.3 3.8	5 2 74
12 13 14 15	Tackling tuberculosis in the indigenous people of New Zealand. Lancet Public Health, The, 2019, 4, e496. Reducing the burden of tuberculosis in the MÄori, the Indigenous people of New Zealand. The Lancet Global Health, 2019, 7, e845. Pyrazolo[1,5- <i>>a</i> >] pyridine Inhibitor of the Respiratory Cytochrome <i>>bcc</i> > Complex for the Treatment of Drug-Resistant Tuberculosis. ACS Infectious Diseases, 2019, 5, 239-249. Association between anti-tuberculosis drug resistance-conferring mutations and treatment outcomes in Myanmar. Infectious Diseases, 2018, 50, 388-390. Overexpression of a newly identified dâ€amino acid transaminase in <i>Mycobacterium smegmatis</i>	6.3 3.8 2.8	5 2 74

#	Article	IF	Citations
19	First 2 Extensively Drug-Resistant Tuberculosis Cases From Myanmar Treated With Bedaquiline. Clinical Infectious Diseases, 2017, 65, 531-532.	5.8	5
20	First- and second-line antituberculosis drug resistance patterns among previous treatment failure patients in Myanmar. Journal of Global Antimicrobial Resistance, 2017, 9, 34-35.	2.2	1
21	Rapid molecular diagnosis of the Mycobacterium tuberculosis Rangipo strain responsible for the largest recurring TB cluster in New Zealand. Diagnostic Microbiology and Infectious Disease, 2017, 88, 138-140.	1.8	8
22	Role of Alanine Racemase Mutations in Mycobacterium tuberculosis <code><scp>d</scp></code> -Cycloserine Resistance. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3. 2	24
23	Evaluation of the genotype MTBDRsl test for detection of second-line drug resistance in drug-resistant Mycobacterium tuberculosis strains in Myanmar. Infectious Diseases, 2017, 49, 865-866.	2.8	1
24	Genotypic diversity of Mycobacterium tuberculosis strains in Myanmar. Infectious Diseases, 2017, 49, 237-239.	2.8	5
25	Draft Genome Sequences of Two Drug-Resistant Mycobacterium tuberculosis Isolates from Myanmar. Genome Announcements, 2016, 4, .	0.8	2
26	Drug-resistant tuberculosis among previously treated patients in Yangon, Myanmar. International Journal of Mycobacteriology, 2016, 5, 366-367.	0.6	2
27	Structure and Function of AmtR in Mycobacterium smegmatis: Implications for Post-Transcriptional Regulation of Urea Metabolism through a Small Antisense RNA. Journal of Molecular Biology, 2016, 428, 4315-4329.	4.2	8
28	Whole-genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates from Myanmar. Journal of Global Antimicrobial Resistance, 2016, 6, 113-117.	2.2	28
29	Novel regulatory roles of cAMP receptor proteins in fast-growing environmental mycobacteria. Microbiology (United Kingdom), 2015, 161, 648-661.	1.8	11
30	A high-throughput screening assay for identification of inhibitors of the A1AO-ATP synthase of the rumen methanogen Methanobrevibacter ruminantium M1. Journal of Microbiological Methods, 2015, 110, 15-17.	1.6	3
31	Hypoxia-Activated Cytochrome <i>bd</i> Expression in Mycobacterium smegmatis Is Cyclic AMP Receptor Protein Dependent. Journal of Bacteriology, 2014, 196, 3091-3097.	2.2	35